Pfizer's stock soared during the coronavirus pandemic because of its COVID-19 vaccine. The world has learned to live with the coronavirus, and Pfizer's stock has plunged as a result. Faced with patent ...

Pfizer appears cheap with a near 7% yield, but capital allocation constraints undermine its investment case. Nearly all of PFE's free cash flow is consumed by dividends, leaving little for buybacks, ...

Pfizer Inc. (NYSE: PFE) is scheduled to provide its full-year 2026 financial guidance on Tuesday, with Bank of America Securities expecting the company's growth profile to closely resemble conditions ...

Pfizer's dividend payout ratio is high, but the company is generated enough free cash flow to cover its dividend. Management remains committed to the dividend program despite Pfizer facing a patent ...